No article text was recorded for this version.
pseudovirus neutralization assay
Version 1 of 1182 papers237 conceptsfrozen 2026-10-04
Papers in this version
- Blog: SARS-CoV-2 antibody prevalence, titres and neutralising activity in an antenatal cohort, United Kingdom, 14 April to 15 June 2020
- Blog: Establishment of a pseudovirus neutralization assay for TGEV
- Blog: Threshold protective levels of serum IgG to Shigella lipopolysaccharide: re-analysis of Shigella vaccine trials data
- Blog: Omicron COVID-19 immune correlates analysis of a third dose of mRNA-1273 in the COVE trial
- Blog: Functional antibody responses to SARS-CoV-2 variants before and after booster vaccination among adults in Ghana
- Blog: Cross-Antigenicity between EV71 Sub-Genotypes: Implications for Vaccine Efficacy
- Blog: Development and Validation of Novel Cell-free Direct Neutralization Assay for SARS-CoV-2
- Blog: In Search of the SARS-CoV-2 Protection Correlate: Head-to-Head Comparison of Two Quantitative S1 Assays in Pre-characterized Oligo-/Asymptomatic Patients
- Blog: Defining the features and duration of antibody responses to SARS-CoV-2 infection associated with disease severity and outcome
- Blog: Immune Correlates Analysis of the mRNA-1273 COVID-19 Vaccine Efficacy Trial
- Blog: Head-to-head evaluation of seven different seroassays including direct viral neutralisation in a representative cohort for SARS-CoV-2
- Blog: P-2051. Assessing SARS-CoV-2 Correlates Protection from Exposed Household Members: A Prospective Cohort Study (AB-PROTECT Study)
- Blog: Immune evasion, infectivity, and membrane fusion of the SARS-CoV-2 JN.1 variant
- Blog: AI designed, mutation resistant broad neutralizing antibodies against multiple SARS-CoV-2 strains
- Blog: Neutralization titer biomarker for antibody-mediated prevention of HIV-1 acquisition
- Blog: Pharmacokinetic serum concentrations of VRC01 correlate with prevention of HIV-1 acquisition
- Blog: Microneutralization assay titer correlates analysis in two phase 3 trials of the CYD-TDV tetravalent dengue vaccine in Asia and Latin America
- Blog: An Expeditious Neutralization Assay for Porcine Reproductive and Respiratory Syndrome Virus Based on a Recombinant Virus Expressing Green Fluorescent Protein
- Blog: Analysis of V2 Antibody Responses Induced in Vaccinees in the ALVAC/AIDSVAX HIV-1 Vaccine Efficacy Trial
- Blog: Potent and broadly neutralizing antibodies against sarbecoviruses induced by sequential COVID-19 vaccination
- Blog: An antibody-dependent enhancement (ADE) activity eliminated neutralizing antibody with potent prophylactic and therapeutic efficacy against SARS-CoV-2 in rhesus monkeys
- Blog: Neutralizing and binding antibodies are a correlate of risk of COVID-19 in the CoVPN 3008 study in people with HIV
- Blog: Examining protective effects of SARS-CoV-2 neutralizing antibodies after vaccination or monoclonal antibody administration
- Blog: V1V2-specific complement activating serum IgG as a correlate of reduced HIV-1 infection risk in RV144
- Blog: Twelve-month specific IgG response to SARS-CoV-2 receptor-binding domain among COVID-19 convalescent plasma donors in Wuhan
- Blog: Immune correlates analysis of a phase 3 trial of the AZD1222 (ChAdOx1 nCoV-19) vaccine
- Blog: Comparing antibody assays as correlates of protection against COVID-19 in the COVE mRNA-1273 vaccine efficacy trial
- Blog: Design and Application of Biosafe Coronavirus Engineering Systems without Virulence
- Blog: Immune correlates analysis of the ENSEMBLE single Ad26.COV2.S dose vaccine efficacy clinical trial
- Blog: Humoral response and neutralising capacity at 6 months post-vaccination against COVID-19 among institutionalised older adults in Argentina
- Blog: 368. A Phase 3, Randomized, Double-blind, Parallel-group Trial to Evaluate the Immunogenicity and Safety of AV7909 for Post-exposure Prophylaxis of Anthrax in Healthy Adults
- Blog: HAI and NAI titer correlates of inactivated and live attenuated influenza vaccine efficacy
- Blog: The Protective Efficacy of a SARS-CoV-2 Vaccine Candidate B.1.351V against Several Variant Challenges in K18-hACE2 Mice
- Blog: Evolution of protective SARS-CoV-2-specific B- and T-cell responses upon vaccination and Omicron breakthrough infection
- Blog: Correlates of protection, thresholds of protection, and immunobridging in SARS-CoV-2 infection
- Blog: Durability of mRNA-1273 vaccine–induced antibodies against SARS-CoV-2 variants
- Blog: Evaluation of candidate vaccine approaches for MERS-CoV
- Blog: Analysis of the Protective Efficacy of Approved COVID-19 Vaccines Against Various Mutants
- Blog: The histamine receptor H1 acts as an alternative receptor for SARS-CoV-2
- Blog: Randomised immunogenicity trial comparing 2019-2020 recombinant and egg-based influenza vaccines among frequently vaccinated healthcare personnel in Israel
- Blog: The Dynamics of Neutralizing Antibody Level in One Year After SARS-CoV-2 Infection
- Blog: Myeloid‐Driven Immune Suppression Subverts Neutralizing Antibodies and T Cell Immunity in Severe COVID‐19
- Blog: The effects of aging and maternal protein restriction during lactation on thymic involution and peripheral immunosenescence in adult mice
- Blog: A quadri-fluorescence SARS-CoV-2 pseudovirus system for efficient antigenic characterization of multiple circulating variants
- Blog: In Vitro Antibody-Dependent Enhancement of SARS-CoV-2 Infection Could Be Abolished by Adding Human IgG
- Blog: Neutralizing antibody correlate of protection against severe-critical COVID-19 in the ENSEMBLE single-dose Ad26.COV2.S vaccine efficacy trial
- Blog: Triterpenoidal Saponins from the Leaves of Aster koraiensis Offer Inhibitory Activities against SARS-CoV-2
- Blog: Effect of HIV Envelope Vaccination on the Subsequent Antibody Response to HIV Infection
- Blog: Estimating the Stoichiometry of HIV Neutralization
- Blog: Impaired B cell immunity in acute myeloid leukemia patients after chemotherapy
- Blog: Enhanced neutralization of SARS-CoV-2 XBB sub-lineages and BA.2.86 by a tetravalent COVID-19 vaccine booster
- Blog: Bovine Herpesvirus-4 Based Vaccine Provides Protective Immunity against Streptococcus suis Disease in a Rabbit Model
- Blog: A novel trifunctional IgG-like bispecific antibody to inhibit HIV-1 infection and enhance lysis of HIV by targeting activation of complement
- Blog: Development of In Vitro Potency Methods to Replace In Vivo Tests for Enterovirus 71 Inactivated Vaccine (Human Diploid Cell-Based/Vero Cell-Based)
- Blog: Molecular and structural insights into SARS-CoV-2 evolution: from BA.2 to XBB subvariants
- Blog: Membrane-wide screening identifies potential tissue-specific determinants of SARS-CoV-2 tropism
- Blog: A Pseudovirus‐Based Method for the Simultaneous Quantitation of Neutralization Antibodies Against All Three Poliovirus Serotypes
- Blog: Germline IGHV3-53-encoded RBD-targeting neutralizing antibodies are commonly present in the antibody repertoires of COVID-19 patients
- Blog: HIV-1 subtype C in vitro growth and coreceptor utilization
- Blog: MVA Vector Vaccines Inhibit SARS CoV-2 Replication in Upper and Lower Respiratory Tracts of Transgenic Mice and Prevent Lethal Disease
Showing 60 of 182 papers.
History & citation
Current · Permanent link
- Quantitative Immune Correlates of Protection for Vaccine Efficacy merged into this direction (65% overlap)
- Pseudotyped Viruses and Surrogate Neutralization Assays merged into this direction (86% overlap)
- Quantifying Protective Immunity Through Functional Neutralization Assays merged into this direction (79% overlap)
- Predicting Vaccine Efficacy Through Immune Correlates merged into this direction (56% overlap)
Cite this direction
Latest version (a living page):
@misc{lacuna_pseudovirus_neutralization_assay_30e2ef4e,
title = {pseudovirus neutralization assay},
author = {{Lacuna}},
howpublished = {Lacuna research direction},
year = {2026},
url = {https://lacuna.tiptreesystems.com/direction/pseudovirus-neutralization-assay/rdr_30e2ef4eb447484a9e86b57e1ae17a83},
note = {Latest version of a living research direction; cite a version for a fixed text. Accessed 2026-11-20},
}This exact version (version 1, frozen text):
@misc{lacuna_pseudovirus_neutralization_assay_30e2ef4e_v1,
title = {pseudovirus neutralization assay},
author = {{Lacuna}},
howpublished = {Lacuna research direction},
year = {2026},
url = {https://lacuna.tiptreesystems.com/direction/pseudovirus-neutralization-assay/rdr_30e2ef4eb447484a9e86b57e1ae17a83/v/1},
note = {Version 1, frozen 2026-10-04. Accessed 2026-11-20},
}